Merck Sees $1.27M in Unusual Call Activity as Stock Hovers Near 52-Week Highs

By TrendSpider Editor

Merck & Company, Inc. is drawing attention in the options market Thursday, with two unusual call contracts generating a combined $1,271,957.90 in total premium. Shares are trading at $144.95, down just 0.30% on the session, but the bullish options flow suggests some traders are positioning for a

Merck Sees $1.27M in Unusual Call Activity as Stock Hovers Near 52-Week Highs

Merck & Company, Inc. is drawing attention in the options market Thursday, with two unusual call contracts generating a combined $1,271,957.90 in total premium. Shares are trading at $144.95, down just 0.30% on the session, but the bullish options flow suggests some traders are positioning for a meaningful move higher. The stock is currently sitting near the upper end of its 52-week range of $78.03 to $156.92, underscoring the elevated stakes of these bets.

Key Drivers of the MRK Stock Move

• Main Catalyst: Two unusual call contracts hit the tape today, spanning strikes at $145 and $155 with expirations in April 2027 and October 2026, respectively. The two contracts combined for $1,271,957.90 in total premium, flagging institutional-level interest in upside exposure.
• Bull Case: The April 2027 $145 call at an at-the-money strike carries an open interest percentage of 966%, meaning volume today dwarfed existing open interest by nearly ten times. That kind of conviction at the ATM strike, backed by $1,236,750 in premium, points to a trader making a sizable directional bet on sustained upside into 2027.
• Bear Case: The October 2026 $155 call is out-of-the-money with a strike roughly 7% above the current price and expires in just over two weeks, on October 16, 2026. With only $35,207.90 in premium behind it and an open interest percentage of just 10%, this contract looks more speculative and faces a tight window to pay off.

The forward setup for MRK is worth watching closely. The stock has spent much of the past year recovering from a multi-year low of $78.03, and at $144.95 it is now within striking distance of its 52-week high of $156.92. The unusual options activity, particularly the heavily loaded April 2027 ATM call, implies that at least one large player sees the current price level as a launching point rather than a ceiling. Whether that thesis holds will depend heavily on pipeline developments and broader pharmaceutical sector sentiment heading into late 2026 and early 2027.

MRK Unusual Options Activity

Two call contracts were flagged as unusual today, with zero put contracts reported. The activity is entirely skewed to the upside:

• Contract 1: Call | Strike: $155 | Expiry: October 16, 2026 | Volume: 689 | Open Interest: 10% of volume | Position: Out-of-the-Money
• Contract 2: Call | Strike: $145 | Expiry: April 16, 2027 | Volume: 850 | Open Interest: 966% of volume | Position: At-the-Money

Total premium across both contracts was $1,271,957.90, with the April 2027 ATM call accounting for the overwhelming majority at $1,236,750. The absence of any put activity reinforces the one-sided, bullish tone of today's flow.

MRK Seasonality

The fourth quarter has historically been an active period for large-cap pharmaceutical names, as year-end portfolio positioning and potential pipeline catalysts drive volume in both the equity and options markets. The placement of one contract expiring mid-October 2026 and another extending into April 2027 suggests traders are layering exposure across multiple potential catalyst windows.

MRK Relative Performance

MRK shares are down just 0.30% on the session, a relatively muted move compared to what the options activity might imply. Trading at $144.95 against a 52-week low of $78.03 and a high of $156.92, the stock has already staged a substantial recovery and is outperforming the broader pharmaceutical sector on a trailing basis. The proximity to the 52-week high suggests Merck has been a relative leader, and the options flow today indicates that momentum may have the attention of institutional traders looking for continued outperformance.